Neoadjuvant T-DM1 and Pertuzumab in HER2+ Breast Cancer Neoadjuvant T-DM1 and Pertuzumab in HER2+ Breast Cancer
Is neoadjuvant T-DM1 plus pertuzumab associated with better event-free survival than conventional neoadjuvant therapy for HER2+ breast cancer?Journal of Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2 | Neoadjuvant Therapy